Lycium barbarum polysaccharides are major bioactive constituents of Lycium barbarum fruit and are widely recognized for antioxidant, immunomodulatory, and intestinal protective activities. Selenium nanoparticles are considered a safer selenium formulation than conventional inorganic selenium because they generally provide improved bioavailability and reduced toxicity. In this study, Lycium barbarum polysaccharide-stabilized selenium nanoparticles were prepared under mild conditions, characterized, and evaluated for antibacterial, antibiofilm, and antidiarrhoeal activities. The optimized nanoparticles exhibited a hydrodynamic diameter of 304.4 ± 32.9 nm, a polydispersity index of 0.369 ± 0.05, and a zeta potential of −20.8 ± 1.5 mV, indicating good colloidal stability. Scanning electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy supported the structural assignment of spherical elemental selenium particles with a polysaccharide-rich surface layer. In vitro assays showed concentration-dependent inhibition of Escherichia coli, with minimum inhibitory and minimum bactericidal concentrations of 100 and 200 μg Se/mL, respectively. Biofilm formation was also markedly reduced, and scanning electron microscopy demonstrated severe bacterial surface damage after treatment. In a KM mouse model of Escherichia coli-induced diarrhea, oral administration of the nanoparticles significantly lowered diarrhea scores, improved body weight recovery, and alleviated intestinal mucosal injury compared with untreated infected mice. Major organs showed no obvious histopathological abnormalities under the experimental conditions. Overall, these findings identify Lycium barbarum polysaccharide-stabilized selenium nanoparticles as a promising selenium-based nanomaterial for controlling bacterial diarrhea and protecting intestinal health. These results provide a practical foundation for future mechanistic, pharmacokinetic, microbiological, and translational studies aimed at broader intestinal applications.
Bovine endometritis frequently progresses to endometrial fibrosis, a leading cause of implantation failure and infertility in dairy cows, yet the upstream events that disrupt endometrial autophagy during uterine inflammation remain poorly defined, and the anti-fibrotic target of quercetin (Que) in the bovine endometrium is unknown. We therefore combined data-independent acquisition (DIA) proteomics of healthy and fibrotic bovine endometria (n = 4 per group) with network pharmacology, molecular docking and a cellular thermal shift assay (CETSA), gain- and loss-of-function studies in TGF-β1-stimulated primary bovine endometrial epithelial cells (BEECs), and a 48 h LPS-induced mouse endometritis model in female C57BL/6 mice. LCN2 was markedly upregulated in fibrotic endometria and was prioritized among five candidate targets; docking predicted binding within the LCN2 pocket, and CETSA showed increased thermal stability of LCN2, consistent with target engagement. In BEECs, LCN2 overexpression activated MAPK/ERK–mTOR signaling, suppressed autophagic flux and promoted epithelial–mesenchymal transition (EMT), whereas LCN2 silencing reversed these phenotypes. Quercetin dose-dependently reduced LCN2 abundance and MAPK/ERK–mTOR phosphorylation, restored autophagic flux and reversed TGF-β1-induced EMT, and ERK inhibition abolished the LCN2-driven phenotype. In LPS-challenged mice, oral quercetin lowered uterine LCN2, recovered autophagy markers and reduced collagen deposition and endometrial damage. These preclinical findings associate LCN2 with impaired endometrial autophagy and EMT and suggest that quercetin may attenuate this cascade; binding affinity, LCN2 dependency and efficacy in cattle were not established and require validation in larger cohorts, purified-protein binding assays and chronic bovine models.
Dihydroartemisinin (DHA) is a bioactive phytopharmaceutical with diverse pharmacological potential, predominantly because of its established antiplasmodial efficacy. Here, we investigated the effects of DHA on metabolic homeostasis in Madin-Darby bovine kidney cells in the context of dose-specific adaptation of metabolism and regulation of biochemistry pathway changes. According to our findings, extensive changes in metabolism were revealed by PCA, accounting for a variability of 59.4% to distinguish contrasting metabolic signatures from normal cells. Metabolomic characterization demonstrated 67 constituting metabolites of baseline cellular processes, while 32 and 44 metabolites have demonstrated differential abundance in low- and high-dose treatments, respectively. Impaired metabolism of glycerophospholipid, amino acid, and nucleotide biosynthesis was reported with implications such as regulation of membrane reorganization, nitrogen metabolism, and cellular bioenergetics. Bioindicators of high-volume lysophosphatidylcholine (18:0) and choline phosphate revealed a lipid homeostatic change, in addition to imbalances in glutamic acid and proline levels. Pathway regulation further modulated ABC transporters and arachidonic acid signaling as implications of systemic phytopharmaceutical-modulated reorganization of metabolism. Hence, the study gives mechanistic insight into DHA-initiated modulation of cellular metabolism in MDBK cells, elucidating its status as a cellular metabolism regulator. Findings confirm the potential of DHA as a phytopharmaceutical in modulating diseases of metabolism, further solidifying its relevance in evidence-based traditional herbal remedies and natural compound therapeutics.